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ABSTRACT Despite considerable progress in identifying
specific HLA alleles as genetic risk factors for some forms of
drug-induced liver injury, progress in understanding whether
genetic polymorphisms relevant to drug disposition also con-
tribute to risk for developing this serious toxicity has been
more limited. Evidence from both candidate-gene case con-
trol studies and genome-wide association studies is now
discussed. In the case of genes relevant to drug metabolism,
p o l ymo r p h i sm s i n c y t o c h r ome s P 4 5 0 , UDP -
glucuronosyltransferases, N-acetyltransferases and glutathi-
one S-transferases as risk factors for DILI are assessed. The
relevance of ABC transporters to drug-induced liver injury is
also considered, together with data showing associations of
particular ABCB11, ABCB1 and ABCC2 polymorphisms
with some forms of drug-induced liver injury. Very few of
the associations with genes relevant to drug disposition that
have been reported have been well replicated. Even appar-
ently well-studied associations such as that between isoniazid
liver injury and N-acetyltransferase 2 slow acetylators remain
problematic, though it seems likely that polymorphisms in
drug metabolism genes do contribute to risk for some specific
drugs. A better understanding of genetic risk factors for drug-
induced liver injury will require further genome-wide associ-
ation studies with larger numbers of cases, especially for forms
of drug-induced liver injury where HLA genotype does not
appear to be a risk factor.
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ABBREVIATIONS
DILI Drug-induced liver injury
GST Glutathione S-transferase
GWAS Genome-wide association study
HLA Human leukocyte antigen
NAPQI N-acetyl-p-benzoquinoneimine
NAT2 N-acetyltransferase 2
SNP Single nucleotide polymorphism
UGT UDP-glucuronosyltransferases
INTRODUCTION
Drug-induced liver injury (DILI) is one of the most common
reasons for drug withdrawal, either at a late stage of the drug
development process or soon after licensing (1). It is also an
important contributor to serious liver disease, though the ma-
jority of DILI cases that lead to acute liver failure are due to
acetaminophen overdose rather than the rarer idiosyncratic
DILI where the disease develops after the causative drug is
used at the recommended dose (2). It is generally considered
that metabolism of the causative drug to a reactive interme-
diate is an important step in the DILI process (3). In addition,
impaired membrane transport in the hepatocyte, affecting
either drug transport directly or bile acid transport, is consid-
ered to be a contributor to DILI, possibly by promoting accu-
mulation of reactive intermediates or of toxic bile acids in
hepatocytes (4). There is extensive data available on the func-
tional significance of a range of polymorphisms in the genes
encoding drug metabolizing enzymes and transporters. This
has enabled studies on the possibility of a relationship between
genotype for biologically plausible polymorphisms in these
genes and risk of DILI development to be performed, resulting
in some interesting observations giving insights into the under-
lying mechanism, though this overall area is still unclear with
an absence of strong effects reported. Most genetic associa-
tions reported to date for DILI relate to HLA genes, pointing
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to an important role for an inappropriate immune response
(5). However, not all forms of DILI show an association with a
particular HLA genotype. The formation of reactive interme-
diates may also contribute to an inappropriate immune re-
sponse so a role for genes contributing to drug disposition
alongside HLA genes in DILI remains plausible.
Cytochromes P450
Because of the ability of the cytochromes P450 tometabolize a
wide range of drugs to reactive intermediates and also the
extent of interindividual variation in levels of P450 enzymes,
polymorphisms in these genes are good candidates as suscep-
tibility factors for DILI. An important role for P450 genes in
DILI susceptibility has not been confirmed to date, though
there are a few reports of associations in relation to particular
drugs. In the concentration-dependent form of DILI seen in
acetaminophen overdose, activation to the N-acetyl-p-
benzoquinoneimine (NAPQI) reactive metabolite is the well
established mechanism for toxicity. A recent study has shown
a strong correlation between levels of total P450-generated
metabolites and serious liver toxicity (6). CYP2E1, CYP1A2
and CYP3A are well established contributors to NAPQI pro-
duction (7). Studies on the relationship between CYP geno-
type and development of DILI following overdose are very
limited but one relatively large study reported a borderline
significant relationship between CYP3A5*1 in patients who
took an intentional overdose and developed acute liver failure
(8). This allele is associated with CYP3A5 expression and
therefore, on average, an overall higher CYP3A activity.
The finding is biologically plausible but needs confirmation
in another similar cohort.
Findings on relationship between CYP alleles and idiosyn-
cratic DILI are quite limited. There is a report from the 1980s
that CYP2D6 poor metabolizers were more susceptible to
perhexiline-induced DILI but, since this drug was withdrawn
soon after the study, follow-up was not possible (9). More re-
cently, a role for another P450 isoform, CYP2B6, in two dif-
ferent forms of idiosyncratic DILI has been suggested. For DILI
due to ticlopidine, an upstream SNP (rs7254579 which results
in -2320T>C) which has been reported to be associated with
increased CYP2B6 expression (10) was significantly more com-
mon among cases (11). It is possible that this variant could be
associated with increased reactive intermediate levels leading to
increased risk of DILI. On the other hand, in cases of DILI due
to efavirenz, the CYP2B6*6 allele appears to be more common
(12). This variant is associated with lower than normal CYP2B6
activity suggesting that for efavirenz, accumulation of the par-
ent drug might be an important factor in DILI.
A possible association between CYP2E1 and DILI due to
isoniazid has been fairly extensively investigated but studies
have not shown consistent associations. This may reflect lim-
ited effects of common CYP2E1 genetic polymorphisms on
enzyme activity and expression and this is still a confusing
area. Most studies concerned the CYP2E1*5 variant
(rs2031920) (an allele often detected using the restriction en-
zyme RsaI) for which the biological significance remains un-
clear (for review see (13)). More detailed studies investigating
other CYP2E1 polymorphisms for this form of DILI might be
worthwhile, though a genome-wide association study (GWAS)
involving 28 cases of isoniazid DILI found no evidence for a
contribution from any CYP2E1 polymorphisms (or other
genes) to susceptibility (14).
UDP-glucuronosyltransferases (UGT)
Members of the UGT family make probably the largest con-
tribution to phase II metabolism of drugs implicated in DILI.
They are relevant as DILI risk factors because of their role in
detoxicating reactive metabolites (or the parent drug) but also
because acylglucuronides generate by glucuronidation of car-
boxyl groups are reactive intermediates which may themselves
bind covalently to proteins triggering direct toxicity or an
inappropriate immune response (15). The main associations
involving UGT genes reported to date for DILI concern acet-
aminophen overdose and idiosyncratic reactions induced by
diclofenac and tolcapone.
A number of different UGT isoforms contribute to acet-
aminophen glucuronidation, including 3 members of the
UGT1A family which all originate from the same UGT1A
gene. Studies with a human liver bank indicated that three
polymorphisms at the 3’-untranslated region correlate with an
increased acetaminophen glucuronidation activity, possibly
due to effects on exon splicing. Carriage of one of these poly-
morphisms (rs8330) appeared to protect against the develop-
ment of acute liver failure in patients who had suffered an
unintentional overdose (16).
Tolcapone, an inhibitor of catechol-O-methyltransferase
used in treatment of Parkinson’s disease, can give rise to ele-
vated transaminase levels in some patients. Several polymor-
phisms in the glucuronidating enzyme UGT1A6 promoter
region were found to be significantly associated with elevated
transaminase levels (17). Because these polymorphisms appear
to be associated with decreased enzyme levels, it was suggested
that the toxicity might be linked to slow metabolism of the
parent drug. It was suggested subsequently that promoter re-
gion polymorphisms in the nearby UGT1A9 may also be
relevant to DILI from this drug (18).
Diclofenac is a widely prescribed non-steroidal
antiinflammatory which is a relatively common cause of
DILI worldwide. This compound undergoes glucuronidation
by UGT2B7. In a study on susceptibility to diclofenac-related
DILI, possession of UGT2B7*2, which is believed to be asso-
ciated with higher than normal glucuronidating activity, was
associated with an increased risk of toxicity (19). This suggests
that the underlying mechanism for toxicity might involve
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production of high levels of diclofenac acylglucuronide. A
slightly larger follow-up study (n= 30) which included some
of the samples from the earlier diclofenac DILI study involved
a genome-wide association study approach. In a substudy of
genes relevant to drug disposition only, SNPs in the UGT2B
region which were in linkage disequilibrium with the
UGT2B7*2-related SNPs were more common in the
diclofenac DILI cases (14).
N-acetyltransferase 2
The phase II enzyme N-acetyltransferase 2 (NAT2) has only a
minor role in drug metabolism generally but a key role in
metabolism of isoniazid, an important drug in the treatment
of tuberculosis (TB), which is usually used in combination with
other drugs. NAT2 is subject to a well studied genetic poly-
morphism with approx. 50% of individuals from a number of
different ethnic groups lacking this enzyme activity entirely,
usually due to the presence of a coding region polymorphism
which affects enzyme stability or activity. Isoniazid is a com-
mon cause of DILI. Acetylhydrazine, an isoniazid metabolite
which can undergo metabolism by cytochrome P450 to a
tox ic metabo l i t e or by NAT2 to the le s s tox ic
diacetylhydrazine, may be the cause of toxicity but the parent
drug, which is seen at higher plasma levels in those with no
NAT2 activity, may also contribute (20). A possible associa-
tion between NAT2 genotype and DILI susceptibility has
been investigated extensively. As reviewed recently, there are
a large number of studies on this aspect with the majority
suggesting that absence of NAT2 activity (slow acetylator phe-
notype) is a risk factor for isoniazid DILI (21). However, the
GWAS discussed above involving 28 cases of isoniazid DILI
did not detect a signal at the NAT2 gene (14). Though reports
showing this association continue to appear (22–24), there are
limitations to most since the studies generally involve very
small numbers of cases and often concern cases with very mild
DILI which is quite common but usually resolves without the
need to discontinue drug treatment. An added complication is
that patients are usually also prescribed pyrazinamide, which
can also cause DILI but is not metabolized by NAT2.
Glutathione S-transferases
The glutathione S-transferases (GST) metabolize a range of
drugs by glutathione conjugation and also have a role in pro-
tection against oxidative stress. Two GST isoforms, GSTM1
and T1, are absent in significant numbers of individuals due to
large gene deletions. Candidate gene studies on GST in rela-
tion to a number of types of DILI have been performed. These
suggest that individuals homozygous null for bothGSTM1 and
GSTT1 are at increased risk of DILI due to troglitazone,
amoxicillin-clavulanate and also possibly a wider range of
drugs (25–27). Data for isoniazid-related DILI is rather
contradictory with two studies reporting an increased frequen-
cy of GSTM1 homozygous null genotypes only (28,29) and a
third increased GSTT1 homozygous null only (30). The find-
ing on troglitazone is consistent with the finding that GSTM1
but not GSTT1 has a role in detoxication of a quinone me-
tabolite of this drug (31) but there appears to be no direct role
for GST in amoxicillin-clavulanate or isoniazid elimination.
Independent replication of these suggested GST associations
is still needed.
ABC Transporters
ABC transporters, including the specific bile acid transporter
BSEP which is encoded by ABCB11, are of considerable in-
terest in relation to DILI, especially for cholestatic forms of the
disease where bile acids accumulate within hepatocytes,
resulting in local toxicity. Other ABC transporters, including
MDR1 and MRP2 which both contribute to biliary excretion
of a range of drugs, are also plausible candidates as DILI risk
factors (4). In addition to genetic variation, inhibition of the
normal ABC transporter function by certain drugs may con-
tribute to risk of DILI (32). It is possible that inhibition may be
more problematic in individuals where transporter expression
or activity is lower than normal due to the presence of genetic
polymorphisms. In general, genome-wide association studies
on DILI have failed to demonstrate any significant signals
from ABC transporters, suggesting that any role as a genetic
risk factor is relatively small (compared with, for example,
HLA genotype) or is specific to only a few specific drugs (14).
Some slightly more positive findings have emerged from can-
didate gene studies.
In a study on a small group of patients who had suffered
DILI relating to a range of different drugs, an association
between cholestatic injury and a polymorphism in exon 13
of ABCB11 was reported (33). The effect on disease risk from
this common polymorphism was small and it therefore seems
unlikely to be a major risk factor for DILI. In a more detailed
study involving genotyping for a larger number of polymor-
phisms including the exon 13 variant, no association with
DILI was detected (34). In contrast to the original finding
about ABCB11 and cholestatic DILI, a further study on the
exon 13 variant suggested that possession of this allele was
associated with increased risk of hepatocellular disease, espe-
cially with non-steroidal antiinflammatory drugs (35).
MRP2 has a major role in the biliary excretion of many
glucuronide conjugates and is encoded by ABCC2. In the
study on diclofenac DILI described above where an associa-
tion with UGT2B7 polymorphisms was detected, carriage of
an upstream polymorphism in ABCC2 (rs717620; −24C>T)
was found to be significantly more common amongDILI cases
(19). This finding is consistent with increased levels of the
reactive diclofenac acyl glucuronide being linked to toxicity
on the basis of findings that −24C>T results in lower
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expression of the MRP2 protein which would favor cellular
accumulation of the glucuronide (36). In a Korean study on
DILI caused by a range of drugs, a polymorphism in linkage
disequilibrium with −24C>T was a significant risk factor for
the development of hepatocellular toxicity whereas a second
promoter region polymorphism was a risk factor for cholestat-
ic or mixed disease (37). These findings regarding ABCC2
−24C>T are in broad agreement with the data on diclofenac
toxicity. In a substudy concerned only with drug disposition
genes which formed part of a larger GWAS on DILI, the
lowest p values for drug disposition-related genes were seen
for a series of ABCC2 polymorphisms (14). More recently, a
study based in Spain on ABC transporter polymorphisms as
risk factors for DILI found some associations with a rare
ABCC2 genotype and also reported an association between
an extended ABCC2 haplotype and disease severity (38).
Genotypes for another transporter gene, ABCB1 which codes
for MDR1, have been studied in patients with DILI due to
nevirapine. In African DILI cases, there was a significantly de-
creased frequency of the ABCB1 SNP 3435C>T (rs1045642)
(39) and a similar association was also reported in a US patient
group (40). However, a subsequent study on a separate group of
European nevirapine DILI patients failed to confirm this associ-
ation (41). No association between ABCB1 polymorphisms and
DILI more generally has been found to date.
Two other ABC transporters, MRP3 and MRP4 (encoded
by the ABCC3 and ABCC4 genes) are found on the basolateral
membrane of the hepatocyte and are also of interest in rela-
tion to DILI susceptibility when data from model systems is
considered. MRP4 is expressed at higher levels thanMRP3 in
human hepatocytes and also appears more important in efflux
of bile acids, especially in cholestasis (42,43). It has been sug-
gested that MRP4 inhibition by some compounds is an im-
portant underlying mechanism for bile acid accumulation in
cholestatic DILI (44). For example, troglitazone and its sulfate
metabolite inhibit both BSEP and MRP4 (45). In the case of
MRP3, inhibition of transport by drugs appears less relevant
to DILI generally but there is evidence that in a Mrp3 mouse
knockout model, basolateral ef f lux of diclofenac
acylglucuronide is lost and that the animals show increased
gastrointestinal ulceration (46). It is possible that hepatic ac-
cumulation of diclofenac acylglucuronide when both MRP2
and MRP3 levels are low due to genetics or drug inhibition
could be a factor in the human liver toxicity (47). However, as
with the other candidate transporter polymorphisms, to date
no association involving ABCC3 (MRP3) has been detected in
a GWAS (14).
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
There are essentially no well-replicated and completely con-
vincing data showing associations between DILI susceptibility
and specific genes relevant to drug disposition. Table I lists
selected examples from those discussed in detail above which
show reasonable biological plausibility but where further con-
firmation is still needed. The availability of GWAS ap-
proaches has added to the complexity since essentially no pre-
viously reported associations (e.g. NAT2 genotype and isonia-
zid DILI) have been replicated in GWAS up to now. GWAS
on DILI has been successful in demonstrating HLA associa-
tions with odds ratios of approx. 2.5 or higher, even when case
numbers are small, but generally other risk factors, which may
well include some of the genes relevant to drug disposition
discussed above, have not yet emerged from these analyses.
The failure to detect these additional risk factors is not neces-
sarily that they don’t exist but possibly because the effect sizes
reported in small candidate gene studies are biased towards
only strongly positive findings being reported. A better under-
standing of genetic risk factors for these rare events will require
larger numbers of well phenotyped cases to be collected and
Table I Selected Associations
Between DILI Susceptibility and
Genes Relevant to Drug
Disposition with Biological
Plausibility
Drug Gene and allele Comments Reference
Acetaminophen CYP3A5*1 Intentional overdose only.
Confirmation needed
(8)
Acetaminophen UGT1A4 rs8330 (2042C>G) Unintentional overdose only.
Confirmation needed
(16)
Diclofenac UGT2B7*2 Candidate gene finding partly
confirmed in additional cases
(14,19)
Diclofenac ABCC2 rs717620 (−24C>T) Confirmation needed (19)
Efavirenz CYP2B6*6 Confirmation needed (12)
Isoniazid NAT2 slow acetylator alleles Association is based on small
studies which generally involve a
mild phenotype. Not yet
confirmed by GWAS.
(14,21)
Ticlopidine CYP2B6 rs7254579 (−2320T>C) Confirmation needed (11)
Tolcapone UGT1A6/1A9 (various SNPs) Confirmation needed (17,18)
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analyzed using GWAS and DNA sequencing approaches.
This is feasible through international collaboration for drugs
in current use. However, where drugs have been withdrawn
from the market due to serious DILI, the number of cases
available for genetic studies may be relatively small and access
to them difficult. The need for larger studies applies to the
more common concentration-dependent toxicity seen in acet-
aminophen overdose as well as to idiosyncratic DILI.
Where the increased risk of an ADR such as DILI due to a
particular genotype is in the order of 1 to 2 fold, the relevance
of this to treatment decisions may be limited. However, this
level of risk from single genetic risk factors is seen for a range of
complex diseases including many cancers and type II diabetes
where large numbers of such risk factors have now emerged
(48). Additive risks or interactions between risk factors may still
determine overall risk. It is already clear that factors such as
age and gender are also predictors of risk for some forms of
idiosyncratic DILI. It may be possible to develop algorithms to
assess individual risk of DILI in the future and these may
include genotype for polymorphisms relating to drug
disposition.
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